Overview: NGS Sleep Disturbance Sequencing TestIntroduction: The NGS Sleep Disturbance Sequencing Test sequences genes to diagnose sleep disorders, causing insomnia or fatigue. Aligned with 2023 AASM guidelines, it uses PCR for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected genetic sleep disorders, such as narcolepsy or circadian rhythm disorders.
Other Names: Sleep Disturbance NGS Assay, Sleep Disorder Gene Panel.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Sleep disorder sequencing began in the 2000s with narcolepsy research. NGS methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Sequences genes to diagnose sleep disorders, guides treatment, and evaluates patients with insomnia or fatigue.
Test Parameters: 1. Sleep Disturbance Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of insomnia, fatigue, or sleep disorder symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document insomnia, fatigue, hypersomnia, or family history of sleep disorders. Include current medications, especially sleep aids.
Consent: Written consent required, detailing the tests purpose, sleep disorder implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze sleep disturbance genes (e.g., HLA-DQB1, PER2). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for sleep disorder diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm sleep disorders, guiding modafinil therapy or genetic counseling. Negative results may require polysomnography.
Specialist Consultation: Consult a sleep specialist or geneticist for result interpretation and treatment planning.
Additional Supporting Tests: Polysomnography, actigraphy, or HLA typing to confirm sleep disorder diagnosis.
Test Limitations: Not all sleep disorders are genetic; clinical correlation is needed. Sample quality affects sensitivity.
References: AASM Sleep Disorder Guidelines, 2023; Sleep, Mignot E, 2022.
